280 related articles for article (PubMed ID: 15751499)
1. Antivascular endothelial growth factor monoclonal antibody therapy: a promising paradigm in colorectal cancer.
Franson PJ; Lapka DV
Clin J Oncol Nurs; 2005 Feb; 9(1):55-60. PubMed ID: 15751499
[TBL] [Abstract][Full Text] [Related]
2. Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer.
Chase JL
Pharmacotherapy; 2008 Nov; 28(11 Pt 2):23S-30S. PubMed ID: 18980549
[TBL] [Abstract][Full Text] [Related]
3. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.
Kabbinavar FF; Hambleton J; Mass RD; Hurwitz HI; Bergsland E; Sarkar S
J Clin Oncol; 2005 Jun; 23(16):3706-12. PubMed ID: 15867200
[TBL] [Abstract][Full Text] [Related]
4. Angiogenesis inhibitors in the treatment of colorectal cancer.
Iqbal S; Lenz HJ
Semin Oncol; 2004 Dec; 31(6 Suppl 17):10-6. PubMed ID: 15696025
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab and oxaliplatin-based chemotherapy in metastatic colorectal cancer.
Beatty GL; Giantonio BJ
Expert Rev Anticancer Ther; 2008 May; 8(5):683-8. PubMed ID: 18471041
[TBL] [Abstract][Full Text] [Related]
6. Targeted therapy in colorectal cancer.
Rajpal S; Venook AP
Clin Adv Hematol Oncol; 2006 Feb; 4(2):124-32. PubMed ID: 16728921
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab in the treatment of metastatic colorectal cancer.
Caprioni F; Fornarini G
Future Oncol; 2007 Apr; 3(2):141-8. PubMed ID: 17381413
[TBL] [Abstract][Full Text] [Related]
8. Targeting angiogenesis in cancer: clinical development of bevacizumab.
Kerr DJ
Nat Clin Pract Oncol; 2004 Nov; 1(1):39-43. PubMed ID: 16264798
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
Shih T; Lindley C
Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
[TBL] [Abstract][Full Text] [Related]
10. The horizon of antiangiogenic therapy for colorectal cancer.
Olszewski AJ; Grossbard ML; Kozuch PS
Oncology (Williston Park); 2005 Mar; 19(3):297-306; discussion 306, 308, 317-33. PubMed ID: 15828549
[TBL] [Abstract][Full Text] [Related]
11. FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer.
Cohen MH; Gootenberg J; Keegan P; Pazdur R
Oncologist; 2007 Mar; 12(3):356-61. PubMed ID: 17405901
[TBL] [Abstract][Full Text] [Related]
12. [Anti-angiogenic treatment and colorectal cancer].
André T; Tournigand C; Abbas F; Louvet C; de Gramont A;
Bull Cancer; 2007 Jul; 94 Spec No():S211-9. PubMed ID: 17846007
[TBL] [Abstract][Full Text] [Related]
13. Overview of anti-VEGF therapy and angiogenesis. Part 1: Angiogenesis inhibition in solid tumor malignancies.
Ellis LM; Rosen L; Gordon MS
Clin Adv Hematol Oncol; 2006 Jan; 4(1):suppl 1-10; quz 11-2. PubMed ID: 16562372
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.
Pohl M; Werner N; Munding J; Tannapfel A; Graeven U; Nickenig G; Schmiegel W; Reinacher-Schick A
Z Gastroenterol; 2011 Oct; 49(10):1398-406. PubMed ID: 21964893
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab in combination with chemotherapy: first-line treatment of patients with metastatic colorectal cancer.
Hochster HS
Semin Oncol; 2006 Oct; 33(5 Suppl 10):S8-14. PubMed ID: 17145525
[TBL] [Abstract][Full Text] [Related]
16. Managing patients with metastatic colorectal cancer on bevacizumab.
Lemmens L; Claes V; Uzzell M
Br J Nurs; 2008 Aug 14-Sep 10; 17(15):944-9. PubMed ID: 18983014
[TBL] [Abstract][Full Text] [Related]
17. The future development of bevacizumab in colorectal cancer.
Díaz-Rubio E; Schmoll HJ
Oncology; 2005; 69 Suppl 3():34-45. PubMed ID: 16301834
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab.
Ellis LM
Nat Rev Drug Discov; 2005 May; Suppl():S8-9. PubMed ID: 15962523
[TBL] [Abstract][Full Text] [Related]
19. First-line treatment of patients with metastatic colorectal cancer: an overview of recent data on chemotherapy plus targeted agents.
Cercek A; Saltz LB
Clin Colorectal Cancer; 2008 Dec; 7 Suppl 2():S47-51. PubMed ID: 19064406
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.
Hurwitz HI; Fehrenbacher L; Hainsworth JD; Heim W; Berlin J; Holmgren E; Hambleton J; Novotny WF; Kabbinavar F
J Clin Oncol; 2005 May; 23(15):3502-8. PubMed ID: 15908660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
